Israel - heprea - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

Israel - heprea - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

Israel - heprea - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

Israel - heprea - Ministry of Health

tzamal bio-pharma ltd - methotrexate 50 mg/ml - solution for injection - methotrexate - psoriasis:because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

Israel - heprea - Ministry of Health

sanofi - aventis israel ltd - fludarabine phosphate 50 mg/vial - powder for solution for inj/inf - fludarabine - palliative treatment of patients with cll refractory to other therapy. treatment of less malignant non-hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. fludara is indicated for the initial treatment of patients with b- cell chronic lymphocytic leukaemia (cll) or after first line therapy, in patients with sufficient bone marrow reserves.

Israel - heprea - Ministry of Health

pharmalogic ltd - oxaliplatin 50 mg/vial - powder for concentrate for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : * adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour * treatment of advanced colorectal cancer.

Israel - heprea - Ministry of Health

salomon,levin & elstein ltd - oxaliplatin 50 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of metastatic colorectal cancer.

Israel - heprea - Ministry of Health

novapharma ltd - oxaliplatin 50 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour .- treatment of metastatic colorectal cancer.

Israel - heprea - Ministry of Health

genmedix - ketamine as hydrochloride 50 mg/ml - solution for injection - ketamine - as the sole anaesthetic agent for diagnostic and surgical procedures. when used by intravenous or intramuscular injection, ketamine is best suited for short procedures. with additional doses, or by intravenous infusion, ketamine can be used for longer procedures. if skeletal muscle relaxation is desired a muscle relaxant should be used and respiration should be supported. for the induction of anaesthesia prior to the administration of other general anaesthetic agents. to supplement other anaesthetic agents. specific areas of application or types of procedure: when the intramuscular route of administration is preferred. debridement, painful dressings and skin grafting in burned patients as well as other superficial surgical procedures. neurodiagnostic procedures such as pneumoencephalograms, ventriculograms, myelograms and lumbar punctures. diagnostic and operative procedures of the eye, ear, nose and mouth including dental extractions.( note: eye movement may persist during ophthalmological procedures). anaes

Israel - heprea - Ministry of Health

salomon,levin & elstein ltd - calcium folinate 50 mg/vial - lyophilized powder for injection - calcium folinate - to diminish the toxicity and counteract the action of folic acid antagonists in cytotoxic therapy. as leucovorin- fluorouracil chemotherapy combinaton for cancer treatment.